Stable Istotope Labelled Blinatumomab Biosimilar – Anti-CD19/CD3E mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Stable Istotope Labelled Blinatumomab Biosimilar - Anti-CD19/CD3E mAb - Research Grade |
|---|---|
| Source | CAS 853426-35-4 |
| Species | Mus musculus |
| Expression system | Mammalian cells |
| Molecular weight | 541kDa |
| Purity | >95% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue Ice |
| Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Aliases /Synonyms | AMG103,BITE MT-103,MEDI-538,MT103,bscCD19xCD3 |
| Reference | PX-TA1067-SIL |
| Related Products | PX-P4004 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | (scFv-kappa-heavy)-(scFv-heavy-kappa) |
| Clonality | Monoclonal Antibody |
| Format | Lyophilized |
| Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
| Isotopic Enrichment | 99% |
| Stability | 1 year |
General information on Anti-CD19/CD3E(Homo sapiens) (Blinatumomab) Monoclonal Antibody
Blinatumomab is a monoclonal antibody constructed by BiTE (bispecific T cell engagers), which is used to treat relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL) with negative Philadelphia chromosome. Blinatumomab is available as a drug under the Blincytoâ„¢ brand.
Contact us
Send us a message from the form below
Reviews
There are no reviews yet.